As a consequence of the pyrosequencing assay design, the assay covered a second CpG +6bp upstream of cg11835197, which on analysis was found to be significantly differentially hypomethylated (p=0.0032, Wilcoxon), with BRAF mutant tumours having a median of 18.5% for mutated tumours and 26.0% for wild type tumours. This evidence concerns the gene BRAF and neoplasm.